Literature DB >> 8752587

Blockade of A2a adenosine receptors positively modulates turning behaviour and c-Fos expression induced by D1 agonists in dopamine-denervated rats.

A Pinna1, G di Chiara, J Wardas, M Morelli.   

Abstract

In rats with unilateral 6-hydroxydopamine lesions of the dopaminergic nigrostriatal pathway, administration of the A2a adenosine antagonist SCH 58261 alone did not induce any motor asymmetry but strongly potentiated the contralateral turning behaviour induced by the dopamine D1 agonist SKF 38393. SCH 58261 also increased the number of Fos-like positive nuclei induced by SKF 38393 in the 6-hydroxydopamine-lesioned striatum. Intense potentiation of D1-dependent turning behaviour and c-Fos expression was also observed after administration of the A2a/A1 antagonist CGS 15943. Administration of the A1 adenosine receptor antagonist DPCPX induced a small potentiation of D1-mediated contralateral turning while c-Fos expression induced by SKF 38393 was not modified. The results suggest that endogenous adenosine acting on A2a receptors can exert an inhibitory influence on the functional expression of D1-mediated responses in dopamine-denervated rats, and propose new possible therapeutic approaches in the treatment of Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8752587     DOI: 10.1111/j.1460-9568.1996.tb01285.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  16 in total

Review 1.  Intramembrane receptor-receptor interactions: a novel principle in molecular medicine.

Authors:  K Fuxe; M Canals; M Torvinen; D Marcellino; A Terasmaa; S Genedani; G Leo; D Guidolin; Z Diaz-Cabiale; A Rivera; L Lundstrom; U Langel; J Narvaez; S Tanganelli; C Lluis; S Ferré; A Woods; R Franco; L F Agnati
Journal:  J Neural Transm (Vienna)       Date:  2006-10-27       Impact factor: 3.575

2.  Neuroprotection induced by the adenosine A2A antagonist CSC in the 6-OHDA rat model of parkinsonism: effect on the activity of striatal output pathways.

Authors:  Jordi Bové; Jordi Serrats; Guadalupe Mengod; Roser Cortés; Eduardo Tolosa; Concepció Marin
Journal:  Exp Brain Res       Date:  2005-06-21       Impact factor: 1.972

Review 3.  Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease.

Authors:  Marie Therese Armentero; Annalisa Pinna; Sergi Ferré; José Luis Lanciego; Christa E Müller; Rafael Franco
Journal:  Pharmacol Ther       Date:  2011-07-23       Impact factor: 12.310

4.  The effects of systemic, intrastriatal, and intrapallidal injections of caffeine and systemic injections of A2A and A1 antagonists on forepaw stepping in the unilateral 6-OHDA-lesioned rat.

Authors:  John E Kelsey; Nicole A Langelier; Brad S Oriel; Catherine Reedy
Journal:  Psychopharmacology (Berl)       Date:  2008-09-13       Impact factor: 4.530

5.  The effect of the adenosine A(2A) antagonist KW-6002 on motor and motivational processes in the rat.

Authors:  Martin O'Neill; Verity J Brown
Journal:  Psychopharmacology (Berl)       Date:  2005-12-13       Impact factor: 4.530

6.  Dopamine-adenosine interactions in the striatum and the globus pallidus: inhibition of striatopallidal neurons through either D2 or A2A receptors enhances D1 receptor-mediated effects on c-fos expression.

Authors:  C Le Moine; P Svenningsson; B B Fredholm; B Bloch
Journal:  J Neurosci       Date:  1997-10-15       Impact factor: 6.167

7.  Effects of adenosine receptor agonists and antagonists in a genetic animal model of primary paroxysmal dystonia.

Authors:  A Richter; M Hamann
Journal:  Br J Pharmacol       Date:  2001-09       Impact factor: 8.739

Review 8.  A critical evaluation of behavioral rodent models of motor impairment used for screening of antiparkinsonian activity: The case of adenosine A(2A) receptor antagonists.

Authors:  Annalisa Pinna; Micaela Morelli
Journal:  Neurotox Res       Date:  2013-12-10       Impact factor: 3.911

9.  Adenosine receptor blockade reverses hypophagia and enhances locomotor activity of dopamine-deficient mice.

Authors:  Douglas S Kim; Richard D Palmiter
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-21       Impact factor: 11.205

10.  Adenosine A(2a) receptor antagonists: potential therapeutic and neuroprotective effects in Parkinson's disease.

Authors:  M Morelli; J Wardas
Journal:  Neurotox Res       Date:  2001-11       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.